Loading…
Legislative Progress
Introduced
February 8, 2011
Latest Action
February 18, 2011
Primary Sponsor
Thaddeus McCotterRepublican(MI)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
57pct
10d open
vs 6,662 other HR bills in the 112th — cohort avg 39d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2012 · fourth_quarter · Defense
HR4310, HR556, and S3254, authorizing and appropriating funds for Fiscal Year 2013 for National Defense, all provisions relating to Research, Development, Test, and Engineering (RDT&E) and all provisions relating to acquisition policies.
Client expense: Not reported · Firm income: $10,000
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Defense
HR4310, HR556, S.3254, and other bills authorizing and appropriating funds for Fiscal Year 2013 for National Defense, all provisions relating to Research, Develoopment, Test, and Engineering (RDT&E) and all provisions relating to acquisition policies.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · second_quarter · Defense
HR4310, HR556, S. 3254 and other bills authorizing and appropriating funds for Fiscal Year 2013 for National Defense, all provisions relating to Research, Development, Test, and Engineering (RDT&E) and all provisions relating to acquisition policies.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2011 · first_quarter · Health Issues
AACC wrote in opposition to H.R. 556, the Preserving Patient Choices Act, which would eliminate section 6301, as amended by sction 10602, of Patient Protections and Affordable Care Act. These provisions are the basis of the new Patient Centered Outcomes Research Institute.
Client expense: Not reported · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE